Lundbeck reports positive results from head-to-head study of antidepressant

Pharmaceutical firm Lundbeck’s antidepressant vortioxetine, which is sold under brand names Trintellix and Brintellix, has demonstrated an advantage in a head-to-head study against desvenlafaxine, which Pfizer is marketing in the US as Pristiq, Lundbeck has announced in a press release.
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Lundbeck finds new CFO
For subscribers